Probenecid inhibits SARS-CoV-2 replication in vivo and in vitro
Abstract Effective vaccines are slowing the COVID-19 pandemic, but SARS-CoV-2 will likely remain an issue in the future making it important to have therapeutics to treat patients. There are few options for treating patients with COVID-19. We show probenecid potently blocks SARS-CoV-2 replication in...
Guardado en:
Autores principales: | Jackelyn Murray, Robert J. Hogan, David E. Martin, Kathy Blahunka, Fred D. Sancilio, Rajiv Balyan, Mark Lovern, Richard Still, Ralph A. Tripp |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Nature Portfolio
2021
|
Materias: | |
Acceso en línea: | https://doaj.org/article/d191ef95cc404745a8ce8416434d12ad |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Drug repositioning of Clopidogrel or Triamterene to inhibit influenza virus replication in vitro.
por: Nichole Orr-Burks, et al.
Publicado: (2021) -
Drug repositioning of Clopidogrel or Triamterene to inhibit influenza virus replication in vitro
por: Nichole Orr-Burks, et al.
Publicado: (2021) -
The in-vitro effect of famotidine on sars-cov-2 proteases and virus replication
por: Madeline Loffredo, et al.
Publicado: (2021) -
Isothermal amplification and fluorescent detection of SARS-CoV-2 and SARS-CoV-2 variant virus in nasopharyngeal swabs.
por: Les Jones, et al.
Publicado: (2021) -
Enhancing the Therapeutic Effect of 2-<sup>211</sup>At-astato-α-methyl-L-phenylalanine with Probenecid Loading
por: Hirofumi Hanaoka, et al.
Publicado: (2021)